These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
2. Company restores access to multiple sclerosis drug after pressure from neurologists. Laurance J BMJ; 2013 Feb; 346():f703. PubMed ID: 23377614 [No Abstract] [Full Text] [Related]
3. Is pharma running out of brainy ideas? Miller G Science; 2010 Jul; 329(5991):502-4. PubMed ID: 20671165 [No Abstract] [Full Text] [Related]
4. New statistics on the cost of new drug development and the trouble with CNS drugs. Lindsley CW ACS Chem Neurosci; 2014 Dec; 5(12):1142. PubMed ID: 25515636 [No Abstract] [Full Text] [Related]
5. The effect of new pharmaceutical agents on pharmacy budgets. Kozma CM Manag Care Interface; 1999 Jan; 12(1):77-8. PubMed ID: 10345243 [No Abstract] [Full Text] [Related]
6. European regulatory experience with drugs for central nervous system disorders. Butlen-Ducuing F; Zienowicz M; Pétavy F; Haas M; Salmonson T; Eichler HG; Rasi G Nat Rev Drug Discov; 2015 Feb; 14(2):89-90. PubMed ID: 25524018 [No Abstract] [Full Text] [Related]
7. 2007 impact factor for the Journal of the Peripheral Nervous System: 2.943. Cornblath DR J Peripher Nerv Syst; 2008 Sep; 13(3):187. PubMed ID: 18844784 [No Abstract] [Full Text] [Related]
8. [Current drug therapies. 1996-7 (1)]. Scheen AJ Rev Med Liege; 1997 Oct; 52(10):631-8. PubMed ID: 9446162 [No Abstract] [Full Text] [Related]
9. Drugmakers plow more resources into autism. Sheridan C Nat Biotechnol; 2013 May; 31(5):367-9. PubMed ID: 23657371 [No Abstract] [Full Text] [Related]
10. An introduction to adaptive designs and adaptation in CNS trials. Dragalin V Eur Neuropsychopharmacol; 2011 Feb; 21(2):153-8. PubMed ID: 20888739 [TBL] [Abstract][Full Text] [Related]
12. New drugs and product approvals from 1999. Gage TW; Taylor SE Tex Dent J; 2000 Sep; 117(9):30-47. PubMed ID: 11857846 [No Abstract] [Full Text] [Related]
13. Japan unveils 5-year plan to boost clinical research. McCurry J Lancet; 2007 Apr; 369(9570):1333-6. PubMed ID: 17455378 [No Abstract] [Full Text] [Related]
14. Drug development for CNS disorders: strategies for balancing risk and reducing attrition. Pangalos MN; Schechter LE; Hurko O Nat Rev Drug Discov; 2007 Jul; 6(7):521-32. PubMed ID: 17599084 [TBL] [Abstract][Full Text] [Related]
16. New drugs and product approvals from 2001. Taylor SE Tex Dent J; 2002 Dec; 119(12):1186-98. PubMed ID: 12592740 [No Abstract] [Full Text] [Related]
18. A comparison of the impact factor and the SCImago Journal Rank index in respiratory system journals. García-Pachón E; Arencibia-Jorge R Arch Bronconeumol; 2014 Jul; 50(7):308-9. PubMed ID: 24315384 [No Abstract] [Full Text] [Related]
19. Population & health services research. Editorial. Frank JD; Mouriquand P; Caldamone A; Malone P J Pediatr Urol; 2013 Oct; 9(5):533-4. PubMed ID: 23942351 [No Abstract] [Full Text] [Related]
20. Evaluating the quality of a journal: JCEHP's 2010 impact factor. Olson CA J Contin Educ Health Prof; 2011; 31(4):223-4. PubMed ID: 22189984 [No Abstract] [Full Text] [Related] [Next] [New Search]